News

Cellectar Biosciences Announces Upcoming Financial Results Call

Cellectar Biosciences Announces Upcoming Financial Results Call

Cellectar Biosciences to Share Financial Insights and Updates

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a prominent name in the biopharmaceutical sector concentrating on cancer treatments, is gearing up to release its financial report for the third quarter that ended on September 30, 2025. This significant announcement is scheduled for November 13, 2025, with a live conference call commencing at 8:30 a.m. Eastern Time.

Details of the Upcoming Conference Call

Cellectar invites all interested parties to participate in this crucial update, which will cover not only the financial aspects but also the latest advancements in their drug development pipeline for cancer treatment.

Conference Call Information

Participants can access the conference call through a toll-free number: 1-800-717-1738. To ensure a smooth experience, it's advisable to have the conference ID ready: 42734. This briefing is an essential opportunity to delve into the company's strategic direction and operational successes.

Corporate Presentation Replay Availability

For those unable to attend the live session, a replay of the presentation will be made accessible within the Events section of the Cellectar Biosciences Investor Relations website shortly after the call ends. This service ensures that all stakeholders can stay informed and updated.

Understanding Cellectar Biosciences and Its Mission

Cellectar Biosciences is dedicated to innovating within the realm of cancer treatments through its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform. This cutting-edge technology is designed to enhance the efficacy and safety of cancer therapies, bringing hope to patients battling various forms of this disease.

Exploring the Product Pipeline

The company boasts an impressive product pipeline featuring several lead assets, including Iopofosine I 131. This targeted therapy aims to deliver iodine-131, a radioisotope, directly to cancer cells, thereby improving treatment outcomes for hematologic cancers and solid tumors like Waldenstrom’s macroglobulinemia and pediatric high-grade gliomas. Additional promising programs target cancers with significant unmet medical needs, including CLR 121125 and CLR 121225.

Recent Milestones and FDA Designations

Iopofosine I 131 is currently undergoing evaluation in Phase 2b clinical trials targeting relapsed or refractory conditions. This development highlights Cellectar's pivotal role in advancing treatment options. Furthermore, this compound has received multiple designations from the FDA, including Breakthrough Therapy and Orphan Drug designations, further indicating its therapeutic potential in oncology.

Connecting with Cellectar Biosciences

To learn more about their initiatives, products, and ongoing research, interested parties are encouraged to visit Cellectar's official website. There, they can find a wealth of information about current cancer treatments and the company's strategic vision. Additionally, following Cellectar on various social media platforms offers another avenue for staying connected with their latest updates and community engagement initiatives.

Investor Relations Contact

For any inquiries, investors can reach out to Anne Marie Fields at Precision AQ via phone at 212-362-1200 or through email at annemarie.fields@precisionaq.com. This connection is vital for those looking to dive deeper into Cellectar's financial and operational strategies.

Frequently Asked Questions

What is the date of the upcoming financial results call?

The financial results call is scheduled for November 13, 2025.

How can I access the conference call?

Participants can call the toll-free number 1-800-717-1738 and should have the conference ID 42734 ready.

What is Cellectar's focus area?

Cellectar Biosciences specializes in developing innovative drugs for cancer treatment, utilizing its proprietary drug delivery technology.

What are the lead assets of Cellectar's product pipeline?

Key products include Iopofosine I 131 and promising compounds targeting various solid tumors and hematologic cancers.

Who can I contact for investor inquiries?

Investors can contact Anne Marie Fields at Precision AQ at 212-362-1200 or annemarie.fields@precisionaq.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 47

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 21

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 20

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 84

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 226

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 77

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 12

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 36

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading

Top 5 Most Recently Viewed Articles

Steel Dynamics Insider Sell: Key Insights and Future Outlook

Updated Category News Views 91

Understanding Recent Insider Transactions at Steel Dynamics In a noteworthy development, James Stanley Anderson, the Senior Vice President of Steel Dynamics (NASDAQ: STLD), executed a substantial sell-off of shares, raising eyebrows among investors and industry analysts alike. This insider transaction, reported through an SEC filing, includes the sale of 10,000 shares,...

Continue Reading
Final Cash Distributions for iShares Premium Money Market ETF

Updated Category News Views 182

Final Cash Distributions Announced BlackRock Asset Management Canada Limited has recently revealed significant cash distributions for the iShares Premium Money Market ETF. This announcement, which is essential for investors looking to optimize their financial strategies, includes details on the cash distributions that will be made available for unitholders. Distribution...

Continue Reading
Sina Corporation Investors Encouraged to Join Class Action

Updated Category News Views 161

Sina Corporation Investors Encouraged to Join Class Action Attention investors of Sina Corporation (NASDAQ:SINA): If you've experienced significant financial losses related to the company's stock, you have a valuable opportunity to take action. A class action lawsuit has been initiated against Sina and its executives. Understanding the Class Action The lawsuit has been...

Continue Reading
Talisker’s Bralorne Gold Project Shows Thriving Ore Sorting Potential

Updated Category News Views 258

Talisker’s Innovative Approach to Ore Sorting Talisker Resources Ltd. is excited to share that promising outcomes have surfaced from its initial testing of ore sorting technologies at the Bralorne Gold Project. This flagship site, situated in British Columbia, is undergoing a revitalization aimed at enhancing gold recovery processes. The success of these technologies...

Continue Reading
Avalanche Experiences Significant Price Surge of 5.53% in One Day

Updated Category News Views 79

Avalanche Sees Impressive Market Performance Avalanche (AVAX) has demonstrated a remarkable surge in the cryptocurrency market, with its price climbing 5.53% in just 24 hours, now sitting at $29.11. This impressive rise is part of a larger trend, as the coin has seen a weekly increase of over 10%, up from $26.40. Notably, the coin has reached an all-time high of $144.96,...

Continue Reading